Clinical trials
Alzheimer’s disease clinical trials
A progressive brain disorder that affects memory and thinking. We’re tracking 601 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07717567Recruiting
Blood tests to diagnose and predict Alzheimer's disease
This study is testing whether a simple blood test can help diagnose Alzheimer's disease and predict how the disease will progress. If you have memory or thinking problems that have been getting worse, you may be able to join.
Milan, MilanoAges 40 years+ - NCT07794670RecruitingPhase 2
Study of obicetrapib for early Alzheimer's disease
This trial tests whether a new drug called obicetrapib can help people who have early signs of Alzheimer's disease but no symptoms yet. It aims to see if the drug can slow or prevent the disease from progressing.
Nashville, TennesseeAges 55–85 - NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT07059871Recruiting
Silkworm powder for nutrition in Alzheimer's disease
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
Hangzhou, ZhejiangAges 50–90 - NCT06956300Recruiting
TMS to help with thinking and memory in aging
This study uses a noninvasive brain stimulation technique called TMS to see if it can slow cognitive decline in older adults who are healthy or have very early signs of Alzheimer's disease. It aims to improve memory and thinking.
Boston, MassachusettsAges 40–99 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT07233512Enrolling by invitation
Periodontal treatment for Alzheimer's disease
This trial tests whether treating gum disease can improve outcomes for people with Alzheimer's disease. If you have mild to moderate Alzheimer's and gum disease, you may be able to join.
LiègeAges Any age - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chandler, ArizonaAges 55–90 - NCT06540833RecruitingPhase 2
Study of a new drug for psychosis in people with Alzheimer's disease
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Anaheim, CaliforniaAges 55 years+ - NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+ - NCT05995418Recruiting
Cost and health impact study for Alzheimer's in China
This study looks at the financial and health effects of Alzheimer's disease and mild cognitive impairment (aMCI) in China. It aims to understand how the disease affects patients and families over time.
BeijingAges 40–100 - NCT02649985RecruitingPhase 1/Phase 2
PET brain scan study for several brain and mood conditions
This early-phase study uses PET and MRI brain scans to better understand brain changes in multiple sclerosis, Alzheimer’s disease, and other neurological or mood conditions. The goal is to test whether these scans can show disease-related differences and guide future treatments.
Boston, MassachusettsAges 18–85 - NCT06170268Recruiting
Alzheimer's registry for treatment and diagnosis
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
Chicago, IllinoisAges 18 years+ - NCT07252440RecruitingPhase 2
Testing an oral drug for early Alzheimer's disease
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
Chongqing, Chongqing MunicipalityAges 55–85 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT06918145Enrolling by invitation
LVA surgery for Alzheimer's disease
This study tests a surgery called lymphaticovenous anastomosis (LVA) as a possible treatment for Alzheimer's disease. The surgery connects tiny lymph vessels to veins to help clear waste from the brain.
Beijing, Beijing MunicipalityAges 50–85 - NCT06338397Recruiting
Social and emotional thinking in Alzheimer's
This study looks at how Alzheimer's disease and similar conditions affect social and emotional thinking. Researchers will use brain scans and questionnaires to understand these changes better.
LilleAges 40–85 - NCT03140865Recruiting
Alzheimer’s disease research core for brain and memory testing
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
Winston-Salem, North CarolinaAges 55 years+ - NCT06385951Recruiting
Virtual reality navigation test for early Alzheimer's detection
This study uses a virtual reality navigation task to detect early signs of Alzheimer's disease. It compares people with mild cognitive problems, mild Alzheimer's, and healthy older adults to see if this test can spot the disease earlier.
Ghent, East-FlandersAges 50–80 - NCT07598617Recruiting
Testing a New Computer Memory Assessment for Early Cognitive Changes
This study evaluates a new computer-based test to detect early memory and thinking changes before they progress to dementia. Researchers are looking for adults 65+ who've noticed subtle cognitive changes in the last 5 years to help refine and test this assessment tool.
Plymouth, DevonAges 65 years+ - NCT05516667Recruiting
Study of Alzheimer’s patients and their families
This study follows people with Alzheimer’s disease and family members over 2 years. It uses regular questionnaires and medical checkups to better understand needs and health changes for patients and caregivers.
France, MarseilleAges 18 years+
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer’s disease?
- Yes. Clin2 currently lists 601 recruiting alzheimer’s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer’s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.